418 related articles for article (PubMed ID: 8806005)
21. Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats.
Ke HZ; Simmons HA; Pirie CM; Crawford DT; Thompson DD
Endocrinology; 1995 Jun; 136(6):2435-41. PubMed ID: 7750465
[TBL] [Abstract][Full Text] [Related]
22. The selective estrogen receptor modulators (SERMs) raloxifene and tamoxifen improve ANP levels and decrease nuclear translocation of NF-kB in estrogen-deficient rats.
Lamas AZ; Nascimento AM; Medeiros ARS; Caliman IF; Dalpiaz PLM; Firmes LB; Sousa GJ; Oliveira PWC; Andrade TU; Reis AM; Gouvea SA; Bissoli NS
Pharmacol Rep; 2017 Aug; 69(4):798-805. PubMed ID: 28591668
[TBL] [Abstract][Full Text] [Related]
23. New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats.
Ma YL; Bryant HU; Zeng Q; Schmidt A; Hoover J; Cole HW; Yao W; Jee WS; Sato M
Endocrinology; 2003 May; 144(5):2008-15. PubMed ID: 12697709
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
Grese TA; Pennington LD; Sluka JP; Adrian MD; Cole HW; Fuson TR; Magee DE; Phillips DL; Rowley ER; Shetler PK; Short LL; Venugopalan M; Yang NN; Sato M; Glasebrook AL; Bryant HU
J Med Chem; 1998 Apr; 41(8):1272-83. PubMed ID: 9548817
[TBL] [Abstract][Full Text] [Related]
25. The preventive and interventional effects of raloxifene analog (LY117018 HCL) on osteopenia in ovariectomized rats.
Li X; Takahashi M; Kushida K; Inoue T
J Bone Miner Res; 1998 Jun; 13(6):1005-10. PubMed ID: 9626632
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological actions of a novel, potent, tissue-selective benzopyran estrogen.
Galbiati E; Caruso PL; Amari G; Armani E; Ghirardi S; Delcanale M; Civelli M
J Pharmacol Exp Ther; 2002 Oct; 303(1):196-203. PubMed ID: 12235251
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the ovariectomized rat model for the evaluation of estrogen effects on plasma cholesterol levels.
Lundeen SG; Carver JM; McKean ML; Winneker RC
Endocrinology; 1997 Apr; 138(4):1552-8. PubMed ID: 9075715
[TBL] [Abstract][Full Text] [Related]
28. Activity of raloxifene in immature and ovariectomized rat uterotrophic assays.
Ashby J; Odum J; Foster JR
Regul Toxicol Pharmacol; 1997 Jun; 25(3):226-31. PubMed ID: 9237325
[TBL] [Abstract][Full Text] [Related]
29. An estrogen receptor basis for raloxifene action in bone.
Bryant HU; Glasebrook AL; Yang NN; Sato M
J Steroid Biochem Mol Biol; 1999; 69(1-6):37-44. PubMed ID: 10418979
[TBL] [Abstract][Full Text] [Related]
30. Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomized rats.
Wu X; Glinn MA; Ostrowski NL; Su Y; Ni B; Cole HW; Bryant HU; Paul SM
Brain Res; 1999 Nov; 847(1):98-104. PubMed ID: 10564741
[TBL] [Abstract][Full Text] [Related]
31. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.
Meunier PJ; Vignot E; Garnero P; Confavreux E; Paris E; Liu-Leage S; Sarkar S; Liu T; Wong M; Draper MW
Osteoporos Int; 1999; 10(4):330-6. PubMed ID: 10692984
[TBL] [Abstract][Full Text] [Related]
32. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits.
Bjarnason NH; Haarbo J; Byrjalsen I; Kauffman RF; Christiansen C
Circulation; 1997 Sep; 96(6):1964-9. PubMed ID: 9323087
[TBL] [Abstract][Full Text] [Related]
33. Water extract of Er-xian decoction selectively exerts estrogenic activities and interacts with SERMs in estrogen-sensitive tissues.
Wong KY; Zhou L; Yu W; Poon CC; Xiao H; Chan CO; Mok DK; Wong MS
J Ethnopharmacol; 2021 Jul; 275():114096. PubMed ID: 33823166
[TBL] [Abstract][Full Text] [Related]
34. Effects of SERM (selective estrogen receptor modulator) treatment on growth and proliferation in the rat uterus.
Stygar D; Muravitskaya N; Eriksson B; Eriksson H; Sahlin L
Reprod Biol Endocrinol; 2003 May; 1():40. PubMed ID: 12777179
[TBL] [Abstract][Full Text] [Related]
35. Estrogen-like activity of tamoxifen and raloxifene on NMDA receptor binding and expression of its subunits in rat brain.
Cyr M; Thibault C; Morissette M; Landry M; Di Paolo T
Neuropsychopharmacology; 2001 Aug; 25(2):242-57. PubMed ID: 11425508
[TBL] [Abstract][Full Text] [Related]
36. Bisphosphonates for prevention of postmenopausal osteoporosis.
Ravn P
Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
[TBL] [Abstract][Full Text] [Related]
37. Specific bone-protective effects of metabolites/derivatives of tamoxifen and clomiphene in ovariectomized rats.
Ruenitz PC; Shen Y; Li M; Liang H; Whitehead RD; Pun S; Wronski TJ
Bone; 1998 Dec; 23(6):537-42. PubMed ID: 9855462
[TBL] [Abstract][Full Text] [Related]
38. Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats.
Cao Y; Mori S; Mashiba T; Westmore MS; Ma L; Sato M; Akiyama T; Shi L; Komatsubara S; Miyamoto K; Norimatsu H
J Bone Miner Res; 2002 Dec; 17(12):2237-46. PubMed ID: 12469918
[TBL] [Abstract][Full Text] [Related]
39. Biochemical bone markers.
Chapman B
CAP Today; 1999 May; 13(5):70-2, 74-8, 78-9. PubMed ID: 10558046
[No Abstract] [Full Text] [Related]
40. Effects of the selective estrogen receptor modulator ospemifene on bone in rats.
Kangas L; Härkönen P; Väänänen K; Peng Z
Horm Metab Res; 2014 Jan; 46(1):27-35. PubMed ID: 24108389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
